- Home
- WETO vs LXEO Comparison
WETO vs LXEO Comparison
Compare WETO & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WETO
- LXEO
- Stock Information
- Founded
- WETO 2019
- LXEO 2017
- Country
- WETO China
- LXEO United States
- Employees
- WETO N/A
- LXEO N/A
- Industry
- WETO
- LXEO
- Sector
- WETO
- LXEO
- Exchange
- WETO NYSE
- LXEO Nasdaq
- Market Cap
- WETO 88.0M
- LXEO 93.9M
- IPO Year
- WETO 2025
- LXEO 2023
- Fundamental
- Price
- WETO $2.71
- LXEO $2.72
- Analyst Decision
- WETO
- LXEO Strong Buy
- Analyst Count
- WETO 0
- LXEO 6
- Target Price
- WETO N/A
- LXEO $18.50
- AVG Volume (30 Days)
- WETO 2.0M
- LXEO 984.8K
- Earning Date
- WETO 01-01-0001
- LXEO 05-12-2025
- Dividend Yield
- WETO N/A
- LXEO N/A
- EPS Growth
- WETO N/A
- LXEO N/A
- EPS
- WETO N/A
- LXEO N/A
- Revenue
- WETO $5,350,773.00
- LXEO N/A
- Revenue This Year
- WETO N/A
- LXEO N/A
- Revenue Next Year
- WETO N/A
- LXEO N/A
- P/E Ratio
- WETO N/A
- LXEO N/A
- Revenue Growth
- WETO N/A
- LXEO N/A
- 52 Week Low
- WETO $1.50
- LXEO $1.45
- 52 Week High
- WETO $4.30
- LXEO $19.50
- Technical
- Relative Strength Index (RSI)
- WETO N/A
- LXEO 44.00
- Support Level
- WETO N/A
- LXEO $2.51
- Resistance Level
- WETO N/A
- LXEO $2.91
- Average True Range (ATR)
- WETO 0.00
- LXEO 0.39
- MACD
- WETO 0.00
- LXEO -0.04
- Stochastic Oscillator
- WETO 0.00
- LXEO 25.00
About WETO WEBUS INTERNATIONAL LIMITED
Webus International Ltd operates on a business model of Mobility-as-a-Service to identify and solve inefficiencies associated with inflexible or low-quality public transportation and provide cost-efficient and customized mass transportation services under different scenarios with comprehensive digital platforms. It offers commute shuttle service, customized chartered bus service, packaged tour service and other service to customers.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.